lenalidomide has been researched along with Erythrophagocytic Lymphohistiocytosis, Familial in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumert, B; Borowiecka, E; Kulig, P; Machaliński, B; Milczarek, S; Osękowska, B; Paczkowska, E; Sommerfeld, K; Zdziarska, B; Łanocha, A | 1 |
| Fukushima, H; Honda, A; Imadome, KI; Iwasaki, A; Jona, M; Kishino, Y; Kurokawa, M; Maki, H; Morita, K; Nishikawa, M; Ushiku, T; Yatomi, Y; Yoshida, M | 1 |
2 other study(ies) available for lenalidomide and Erythrophagocytic Lymphohistiocytosis, Familial
| Article | Year |
|---|---|
Secondary Hemophagocytic Syndrome in a Patient with Plasma Cell Myeloma and CNS Involvement Treated with Lenalidomide.
Topics: Adult; Diagnosis, Differential; Humans; Immunomodulating Agents; Lenalidomide; Lymphohistiocytosis, Hemophagocytic; Multiple Myeloma; Neoplasms, Second Primary | 2022 |
Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.
Topics: Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunomodulating Agents; Lenalidomide; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Multiple Myeloma | 2023 |